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Abstract
Background: The use of intravenous thrombolysis for stroke is limited by contraindications that may be difficult to
identify promptly and accurately. Evidence supports the use of information technology-based clinical decision support
(CDS) tools to achieve improvements in care delivery. The objective of this pilot study was to investigate the efficacy of
a CDS tool to screen health records for contraindications to intravenous stroke thrombolysis.
Methods: A CDS tool was developed to rapidly screen health information in seven affiliated hospitals for
contraindications to stroke thrombolysis. A fixed-sequence, 2-period crossover study was conducted to test the
efficacy of the CDS tool. Four mock patient records derived from the stroke registry that contained a total of
nine contraindication items in two or more of the hospitals were used for testing purposes. The test patients
were preset and balanced between groups with and without the CDS tool appearing six times in each group
before recruiting the participating physicians. Physicians who were responsible for thrombolytic therapy and
willing to sign informed consent were recruited. The participating physicians were asked to check a list of
contraindications for two of the patients by using a shared electronic medical record system among the seven
hospitals with and without the CDS tool. The test time and missed contraindications were recorded and
analyzed statistically.
Results: A total of 14 physicians who were responsible for stroke thrombolysis were approached, and 12 signed
informed consent and took the test. By using the CDS tool, the test time was reduced significantly from 14.6 ± 7.4 to
7.3 ± 5.2 min (P = 0.010). In a total of 54 contraindications, the number of missed contraindications was reduced
significantly from 23 (42.6 %) to seven (13.0 %) (P = 0.001). The difference of missed contraindication number
between the two groups was statistically significant either per physician or per contraindication item.
Conclusions: By screening health records for relevant contraindications, the use of a CDS tool may reduce the
time needed to review medical records and reduce the number of missed contraindications for stroke
thrombolysis.
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Background
Strong evidence supports the use of clinical decision
support (CDS) tools and computerized provider order
entries [1]. A systematic review of the literature shows
that most studies report that health information technol-
ogy (IT) interventions had statistically and clinically sig-
nificant benefits on health care [1].
Intravenous thrombolysis with tissue-type plasmino-
gen activator (tPA) for acute ischemic stroke is recom-
mended by stroke guidelines [2]. However, the beneficial
effects of this treatment are highly time-dependent [3].
Because of the risk of hemorrhage, and especially intracere-
bral hemorrhage, the use of intravenous tPA thrombolysis
is limited by certain criteria, especially contraindica-
tions [4]. Major deviations from protocol may place pa-
tients at a higher risk of in-hospital mortality, serious
extracranial hemorrhage and symptomatic intracerebral
hemorrhage [5, 6]. A detailed medical history of pa-
tients with regards to contraindications for treatment
must be taken carefully and promptly from the patients
themselves and/or family members to avoid complica-
tions. However, this may not always be possible when
the patient is confused or aphasic. In these situations,
health IT systems may provide an opportunity for safer,
more efficient care.
Changhua Christian Hospital (CCH) is one of the
major providers of intravenous thrombolysis treatment
for stroke in Taiwan [7]. The safety and efficacy of
treatment have been shown to be comparable to other
Asian and Western countries [7, 8]. Changhua Chris-
tian Healthcare System (CCHS) is composed of CCH
and six affiliated hospitals in the surrounding area in
western Taiwan, covering a population of about 1.5 mil-
lion people. CCHS developed a CDS tool, CCHS iStroke,
to allow for the rapid screening of a relevant medical
history for stroke patients requiring thrombolysis. The




Patients who visit CCHS hospitals for medical care are
covered by the National Health Insurance program in
Taiwan. Through this program, insured patients are free
to visit any hospital at any time. Medical records at the
affiliated hospitals can be accessed from CCH through a
shared electronic medical record system (EMR) via a
secured internet link. Patients who visit CCHS hospitals
are encouraged to sign informed consent to allow for
sharing health information among the CCHS hospitals,
and treating physicians are authorized to obtain their
medical records remotely from hospitals within CCHS if
they have signed such consent.
CCHS iStroke
There are a number of contraindications including med-
ical history, medication use, and adverse drug responses
for intravenous thrombolysis with tPA for acute ische-
mic stroke. In a total of 26 contraindications, 17 (65 %)
are regarding information that can be extracted from
medical records reported before the stroke. Contraindi-
cations that contain searchable items were identified, in-
cluding adverse drug response records, anticoagulant
use, and International Classification of Diseases codes in
admission and out-patient records (Additional file 1:
Table S1). The CCHS iStroke was developed to allow for
rapid screening of the relevant medical history for stroke
thrombolysis among all electronic CCHS hospital re-
cords to support clinical decision making. The CCHS
iStroke is composed of two parts: a database and a hand-
held device with application software (app) that can
access the database. The database is independent from
the shared EMR and generated by searching contraindi-
cations from the shared EMR of all affiliated hospitals
for every patient who has ever visited CCHS and signed
informed consent. The database is updated on a daily
basis. The app accesses the database for a specific pa-
tient profile when code stroke is activated for that pa-
tient. The app also synchronously accesses the shared
EMR of the seven hospitals for contraindications, labora-
tory results, and brain imaging results that were gener-
ated in the last 24 h (Fig. 1). The app includes forms for
National Institute of Health Stroke Scale score assess-
ment, treating criteria assessment, physician visit time
record, informed consent, tPA dose calculator, relevant
laboratory results, computed tomography images of the
brain, and a visual aid for risk communication (Fig. 2).
The result of contraindication item search is presented
below the checkboxes of the item when the physician as-
sesses for treating criteria (Fig. 2). The treating physician
could further confirm this information with the patient
and/or family member(s) or by checking the EMR to be
able to make a clinical decision for thrombolysis more
rapidly and accurately. All clinical information generated
in the app including total dose of tPA and results of
National Institute of Health Stroke Scale score are re-
corded in the database and can be printed as needed.
Evaluation of the CCHS iStroke
The Institutional Review Board Committee A at CCH
approved this study for human subjects. Written informed
consent was obtained from all participants. To limit situ-
ational variables and increase the significance, four mock
patient records were generated. These records were de-
rived from the stroke registry that contained records from
two or more CCHS hospitals [7]. Relevant medical histor-
ies were found in the shared EMR in four of the seven
hospitals. Some relevant medical histories were identified
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Fig. 1 Changhua Christian Healthcare System iStroke system. CCH: Changhua Christian Hospital; ECH: Erlin Christian Hospital; ICD: International
Classification of Diseases; LCH: Lukang Christian Hospital; NCH: Nanto Christian Hospital; YCH: Yunlin Christian Hospital;YMH: Yomin Hospital; YSH:
Yuanshen Hospital . The authors own the copyright for the map image
Fig. 2 A screenshot of Changhua Christian Healthcare System iStroke. CT: computed tomography; NIHSS: National Institue of Health Stroke Scale;
TPA: tissue-type plasminogen activator
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not because they excluded treatment, but because more
attention was required for their consequences or related
treatment. For example, a history of atrial fibrillation did
not fulfill the exclusion criteria; however patients receiving
anticoagulation therapy for atrial fibrillation may be ex-
cluded from treatment. A history of dementia was found
in all test cases, however none fulfilled the exclusion cri-
teria (advanced dementia). Table 1 shows the relevant
medical histories and related contraindications in the four
test cases. Of the 17 total contraindications for stroke
thrombolysis that can be extracted from the EMR, the
four cases had six different and a total of nine contra-
indications. Case 2 had a record of liver cirrhosis at Nantou
Christian Hospital that met contraindication item 13. Case
2 also met contraindication item 15 (hemodialysis) as the
risk of bleeding was considered to outweigh the benefits of
therapy. Case 3 had a record of intracranial hemorrhage at
CCH in 2010 that fulfilled contraindication item 1. Case 4
was taking anticoagulants from CCH and thus fulfilled
contraindication item 16. Three of them met contraindica-
tion item 17 for a known history of diabetes and stroke.
A pilot study using a fixed-sequence, 2-period cross-
over design was conducted to study the efficacy of the
CDS tool. The test patients were preset and balanced
between groups with and without the CDS tool so that
each mock patient appeared six times in each group
before recruiting the participating physicians. Physicians
who were responsible for thrombolytic therapy at CCH
and were willing to perform the test of the CCHS
iStroke during off-duty hours were recruited and in-
formed consent was obtained. The total number of par-
ticipating physicians was set at 12 because that each
mock patient appeared six times in both groups with
and without the CDS tool.
Each participant was presented with a set of stroke test
cases. Each case began with the scenario of the patient
arriving at CCH within 1 h of the stroke onset (Fig. 3). It
was not possible to obtain any useful information
regarding contraindications from the test case or his/her
family members. For the control case, the participating
physician was asked to check a list of contraindications
for two test cases by using the shared EMR only (the
control group). In the intervention case, the participant
was asked to check a list of contraindications for another
two test cases by using both shared EMR and CCH
iStroke (the iStroke group). The time taken for the test
and the number of missed contraindications were re-
corded for each set of test cases.
Analysis
The missed contraindications were analyzed according
to the participating physician. The time taken to review
the medical records and the number of missed contrain-
dications were compared statistically between the con-
trol and iStroke groups. Univariate analysis was carried
out using unpaired t, Mann–Whitney, and χ square
tests, whenever applicable. All statistically significant
levels were defined as P < 0.05.
Results
Every test case appeared six times in each group. There
were a total of 54 contraindication items (6 × 9 items) in
either the control or iStroke group. A total of 14 physi-
cians who were responsible for thrombolytic therapy at
CCH were approached consecutively, 12 of whom signed
informed consent and were recruited for the test. Table 2
shows the characteristics of the 12 participating physi-
cians. All of them had 3 or more years of clinical ex-
perience, and most had experience of intravenous
thrombolysis with tPA for acute ischemic stroke in 10
or more patients.
Table 3 shows a summary of the missed contraindications
according to the participating physician. All participating
physicians had at least one missed contraindication in the
control group. Contraindication items 3, 13, and 17 were
among the most frequently missed items. Notably, two phy-
sicians missed contraindication item one (previous intracra-
nial bleeding at any time) and one missed item 16 (patient
having received oral anticoagulants such as warfarin, dabi-
gatran, or rivaroxaban) in the control group. Eight of the 12
physicians did not miss any contraindications in the iStroke
group. Compared to control group, the number of missed
contraindications was lower in the iStroke group in nine
(75 %) of the participating physicians. Two had the same
number of missed contraindications in both groups, and
one had more missed items in the iStroke group.
Table 1 Relevant medical history and contraindication items fulfilled according to the test cases
Cases Medical history (Hospital, Year) Contraindication item
1 Dementia (YCH, 2007); Diabetes (YCH, 2009); Ischemic stroke (CCH, 2012); Stroke in 3 months (YCH, 2014) 3, 17
2 Atrial fibrillation (NCH, 2010); Dementia (NCH, 2010); Diabetes (NCH, 2010); Heart failure (NCH, 2008); Hemodialysis
(CCH, 2000); Ischemic stroke (NCH, 2009); Liver cirrhosis (NCH, 2009)
13,15,17
3 Atrial fibrillation (CCH 2012); Dementia (ECH, 2012); Heart failure (ECH, 2011); Intracranial hemorrhage (CCH, 2010);
Ischemic stroke (CCH, 2012)
1
4 Atrial fibrillation (YSH 2005); Dementia (CCH, 2014); Diabetes (CCH, 2011); Ischemic stroke (CCH, 2011); Rivaroxaban use
(CCH 2014); Stroke in 3 months (CCH, 2014); Warfarin use (CCH 2014)
3, 16,17
CCH: Changhua Christian Hospital; ECH: Erlin Christian Hospital; NCH: Nanto Christian Hospital; YCH: Yunlin Christian Hospital
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Table 4 shows the time taken for the test and the
number of missed contraindications in the control and
iStroke groups. The time was 14.6 ± 7.4 min in the con-
trol group and was only 7.3 ± 5.2 min in the iStroke
group (P = 0.010). The total number of missed contra-
indication count was 23 in the control group and was
only seven in the iStroke group (P = 0.001). The differ-
ence of missed contraindication count between the two
groups was statistically significant either per physician
or per contraindication item.
Discussion
A recent review identified 26 currently available tools to
support decision making or patient understanding in the
treatment of acute ischemic stroke with intravenous
thrombolysis [9]. Most of these tools were related to patient
information and risk communication. Three of these were
electronic tools that used predictive equations to calculate
outcomes for individual patients. However, none of them
were related to active screening of guideline or licensed
contraindications that may be critical and time-consuming
when making a decision for treatment [9]. Our results dem-
onstrate the feasibility of a CDS tool of this kind.
Reports on the off-label use of tPA have shown that
current guideline or licensed contraindications are subject
to change [10]. A retrospective study analyzed protocol vio-
lations and rates of symptomatic intracerebral hemorrhage,
and showed that protocol violations occurred in 36 % of
enrolled patients. Nevertheless, there was no significant
increase in the incidence of symptomatic intracerebral
hemorrhage in these patients [11]. However, most common
violations in the report were related to a 3 h-time window
and blood pressure rather than other contraindications.
Medico-legal issues are a concern in tPA thrombolysis for
acute ischemic stroke. Although the rate of litigation claims
involving complications from treatment was low in a recent
review, fatal or poor outcomes may be a triggering factor
for litigation [12, 13]. The incidence of symptomatic intra-
cerebral hemorrhage in patients receiving intravenous
thrombolysis for acute stroke has been reported to range
from 2 to 6 %, and such cases are prone to legal litigation if
a protocol violation has occurred [14]. Treatment following
current guideline and licensed criteria may be the best
choice, especially for clear-cut contraindications.
In our study, two physicians missed contraindication
item 1 (previous intracranial bleeding at any time) and
one missed contraindication item 16 (patient having re-
ceived oral anticoagulants such as warfarin, dabigatran,
or rivaroxaban) in the control group. However, none
were missed in the iStroke group. Therefore, the CCHS
iStroke may be a useful CDS tool to prevent medico-
legal issues.
It has been demonstrated that small reductions in the
delay of thrombolysis for stroke result in significant and










#1 34 M 7 ≧10 1,2 3,4
#2 38 M 13 ≧10 1,3 2,4
#3 34 M 4 ≧10 1,4 2,3
#4 30 M 4 ≧10 2,3 1,4
#5 32 M 3 4-6 2,4 1,3
#6 30 M 3 ≧10 3,4 1,2
#7 53 M 25 4-6 1,2 3,4
#8 43 M 14 ≧10 1,3 2,4
#9 31 M 3 7-9 1,4 2,3
#10 43 M 18 ≧10 2,3 1,4
#11 47 M 17 ≦3 2,4 1,3
#12 31 F 5 ≧10 3,4 1,2
aintravenous thrombolysis with tissue-type plasminogen activator for acute ischemic stroke
Fig. 3 Study profile. CCHS: Changhua Christian Healthcare System
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Table 4 Test results of control and iStroke groups
Control iStroke P
Time, minutes, mean ± SD 14.6 ± 7.4 7.3 ± 5.2 0.010
Total missed contraindication counts, n (%a) 23 (42.6) 7 (13.0) 0.001
Missed contraindication counts per physician
Mean ± SD 1.9 ± 0.7 0.6 ± 1.0 0.001
Median 2.0 0 0.002
Missed contraindication counts per item
Mean ± SD 3.8 ± 2.5 1.2 ± 1.5 0.047
Median 3.5 1.0 0.027
SD standard deviation
aMissed item number in 54 (9 items × 6) contraindication items in each group
Table 3 Missed contraindication items according to the participating physicians
Physician Item #1 Item #3 Item #13 Item #15 Item #16 Item #17 c i Total
#1 c 1(2) 1(1) 2 2
i 0
#2 c 1(3) 1(1) 2 2
i 0
#3 c 1(4) 1 1
i 0
#4 c 1(2) 1 1
i 0
#5 c 1(4) 1(2) 2 2
i 0
#6 c 1(4) 1(4) 2 4
i 2(1、2) 2
#7 c 1(2) 1(2) 2 2
i 0
#8 c 1(3) 1 2
i 1(4) 1
#9 c 1(4) 2(1、4) 3 3
i 0
#10 c 1(2) 1(2) 2 3
i 1(4) 1
#11 c 1(4) 1(4) 1(4) 3 3
i 0
#12 c 1(4) 1(4) 2 5
i 1(2) 1(2) 1(1) 3
c 2 6 5 2 1 7 23
i 0 1 1 1 0 4 7
Total 2 7 6 3 1 11 30
c control; i iStroke
Data shown as missed item count (test case number)
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robust average health benefits over the patients’ lifetime,
with each minute of onset-to-treatment saved granting on
average 1.8 days of extra healthy life [15]. Efforts should
therefore be made to shorten the time required to make a
decision. The use of the CCHS iStroke in our study
resulted in a 50 % reduction in the time required to review
medical records, and a 70 % reduction in the number of
missed contraindications. The CCHS iStroke may there-
fore be an efficacy CDS tool to decide whether or not to
initiate thrombolysis for stroke patients.
There are several limitations to this study. The use of
mock patient records may be a better way to standardize
the process and shorten the time required for testing.
However, further studies in real world practice are re-
quired to investigate its effectiveness. Another limitation
is that some contraindications for stroke thrombolysis
were not included in our tool because of the requirement
to measure them on site, including severe stroke with a
National Institute of Health Stroke Scale score >25, plate-
let count ≤100,000/mm3, blood glucose level, and blood
pressure. The CCHS iStroke was designed to support de-
cision making rather than actually making the decision,
and the final clinical decision is left to the treating phys-
ician. In addition, the screening protocol of the CCHS
iStroke depends on searchable items defined by the
hospital IT department and is thus subject to change. Our
database includes patient records of one medical center
(CCH) and six nearby community hospitals with a total of
3047 beds. It was an advantage to have all relevant
medical records in the same healthcare system connected
by a shared EMR, however this may not apply to hospitals
in other areas. Nevertheless, the CCHS iStroke may be
used within a single hospital.
Conclusions
Our results of this pilot study demonstrate that the
CCH iStroke may be an efficacy tool to support decision
making for when to initiate intravenous thrombolysis for
patients with acute ischemic stroke. Further studies in
real world practice are required to investigate its clinical
effectiveness.
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